ProBioGen, ImmunOs Ink Manufacturing Services Agreement

ProBioGen AG, together with ImmunOs Therapeutics AG, signed a manufacturing services agreement for ImmunOs' novel platform of multitasking biologics. ProBioGen will support ImmunOs in the development of their biologics using its recently launched DirectedLuck Transposase technology and conducting large scale GMP manufacturing. ImmunOs has a pipeline of novel agents in development.
 
"We are pleased about this confidence in our expertise," said Wieland Wolf, chief executive officer, ProBioGen. "It is our goal enabling ImmunOs to start clinical trials with this promising molecule in a timely manner. We are very passionate to develop a cell line and respective robust processes based on our innovative technologies to deliver their product with highest quality."

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.